Make Computer System Validation more predictable: The pragmatic guide

Why CSV frays without a cadence

Most validations fail not from a lack of competence, but from a lack of cadence. A system is procured, the validation “runs along”, and after three months there is a stack of half-finished documents whose relationship to one another no one can fully reconstruct any longer. The risk then shifts from the software to the validation process itself.

The counter-design is not “work faster”, but cut more tightly and close more clearly. When every phase has a defined entry and exit document, the validation becomes verifiable — not only at the end, but in every step. The eight weeks described here are exactly that: a structure that makes the start and end of each phase visible. They are not a promise that every system is validated in eight weeks. A single SaaS tool with low GxP risk can be faster; a deeply integrated MES with custom configuration takes longer.

Most validations fail not from a lack of competence, but from a lack of cadence.

Phase 1 (week 1–2): scope and risk classification

The first phase decides on all the following. First you clarify the system type by GAMP 5 category: a standard product without configuration (category 3), a configured product (category 4) or custom software (category 5). The category determines the validation depth — it is not a label but the logic behind how much you have to test.

In parallel, you carry out a risk-based classification: which functions affect patient safety, product quality or data integrity? GAMP 5 in the 2nd Edition consistently puts this risk-based approach and critical thinking at the center — the effort is governed by the risk, not by a blanket “test everything” rule. The FDA describes a comparable risk-based logic in Computer Software Assurance, but for software used in medical-device production or the quality management system under 21 CFR Part 820. For this pharmaceutical CSV guide it serves only as methodological orientation; it does not establish 1:1 applicability.

The result of this phase is a validation plan (or validation master plan, depending on scope) that defines scope, risk classes, responsibilities and deliverables. If it is cleanly cut here, the scaffolding for everything else is in place.

Phase 2 (week 2–4): URS and functional specification

The User Requirements Specification (URS) describes what the system must be able to do from the user's and GxP perspective — formulated testably, each requirement uniquely identifiable. A requirement you cannot test does not belong in the URS but in a design note. The URS is the backbone of the later traceability: what is not stated here is hard to prove later.

The functional specification (FS) translates the requirements into concrete system behavior — how the system fulfills the URS. For category 3 standard products it is often lean, because it builds on supplier documentation; for configured or custom systems it becomes more extensive. What matters is the source situation: supplier documentation, configuration states and design decisions must be available and released before you use them as a validation basis. Sources first, then derive — not the other way around.

Phase 3 (week 4–7): IQ, OQ and PQ

Now testing happens. The three classic qualification stages build on one another:

• Installation Qualification (IQ): Is the system installed correctly and per specification? Environment, versions, interfaces, configuration in the documented target state.
• Operational Qualification (OQ): Does the system function across the intended operating range as specified? Here the focus is on GxP-critical functions — risk-based, not blanket.
• Performance Qualification (PQ): Does the system fulfill its purpose under real operating conditions and with real processes? This is where it shows whether the validation hits the actual use case.

The risk-based approach has its strongest effect in this phase. For a standard product with established supplier qualification, a targeted, verifying test can suffice, while critical custom functions demand deeper testing. Within its medical-device production/QMS scope, the FDA CSA guidance describes different assurance activities depending on risk — from script-based testing to unscripted, exploratory testing. Outside that scope, this is methodological orientation; the applicable requirements remain decisive. What matters is that every test requirement, every result and every deviation is documented and released before the system goes into GxP use.

Phase 4 (week 7–8): traceability and review

A validation is only prepared in a defensible way when it is fully traceable. The traceability matrix links each URS requirement to the relevant specification and to the test or justified assessment that covers it. This makes the lifecycle traceability required by EU GMP Annex 11 § 4.4 demonstrable. If a link is missing, the evidence remains incomplete.

The conclusion is the validation report: summary of activities, assessment of deviations and a final recommendation on the outcome. In the EU GMP context, validation documents are approved and authorised by the appropriate personnel defined in the pharmaceutical quality system; a formal release to the next stage is authorised by the relevant responsible personnel. The pharmaceutical quality system determines whether QA holds an approval role. This is exactly where the point of the cadence lies: when the preceding phases have been cleanly completed, the final review is a confirmation, not a repair marathon.

Where AI helps — and where the human decides

The biggest time sink in CSV is rarely the thinking, but the producing, cross-linking and keeping consistent of documents: URS from requirements, test cases from the functional specification, the traceability matrix across all of it. This is exactly where AI can suggest drafts and make gaps visible — but it replaces neither the expert assessment nor the release.

traqx's trust architecture is designed for this: sources first — derivations are produced on the basis of released documents, not from the model's memory. AI as a suggestion — every draft is a suggestion, not a finished result. The human decides — review and release remain with the responsible roles designated in your pharmaceutical quality system. The audit trail remains — who reviewed and released what when on which basis is traceable. This is the only form of acceleration that holds in a regulated environment: speed in creation, without compromise on traceability and responsibility.

Frequently asked questions

Is CSV in eight weeks guaranteed?

No. Eight weeks describes a possible cadence here, not a binding delivery or outcome promise. Actual duration depends on factors such as scope, GxP risk, system category, suppliers and the availability of expert roles.

What makes CSV more predictable?

A clear scope, risk-based test depth, fixed review gates and end-to-end traceability make dependencies visible early. This turns the final review into confirmation rather than a repair round.

Where can AI support CSV?

AI can prepare source-bound drafts, consistency checks and traceability suggestions. Review and release remain human decisions made by the responsible roles designated in the pharmaceutical quality system.